glp 1 drugs for obesity GLP-1 Medications Weight Loss: How to Get Started | News Medical Weight Loss Solutions |

While this supports patient access, compounded therapies threaten the clinical value story of FDA-approved weight-loss therapies

Research on both mice and humans has highlighted the essential role of IL-33 in stimulating ILC2s and Th2 cells to secrete type 2 cytokines, such as IL-5 and IL-13, which trigger allergic responses driven by the innate immune system [178,179,180]

Firstly because of the abundance of GLP-1 receptors in the brain, and secondly because the brain and the immune system communicate with all organs in the body (Lunenfeld-Tanenbaum Research Institute)

In most states, Medicaid will not cover GLP-1s for obesity though some doctors are finding ways around this by prescribing Ozempic rather than Wegovy

That, combined with possible nutritional deficiencies from eating less, could lead to shedding

In February 2025, the FDA announced that the shortage of semaglutide injectable products (Ozempic, Wegovy) has been resolved, Dulaglutide (Trulicity) shortage resolved in June 2025